Tarantula's venom used to develop heart drug
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The venom of the tarantula spider is being used to develop a revolutionary drug to combat heart flutter, one of Britain's commonest cardiac disorders.
The venom of the tarantula spider is being used to develop a revolutionary drug to combat heart flutter, one of Britain's commonest cardiac disorders.
Scientists have discovered that a small protein, or peptide, isolated from the venom of Grammostola spatulata - a hairy tarantula that can grow to the size of a man's hand - can significantly inhibit cardiac arrhythmia, when heart muscle goes into uncontrolled spasms.
The researchers, led by Frederick Sachs of the State University of New York in Buffalo, believe that the peptide, called GsMtx-4, could become the first drug developed that is specifically directed against arrhythmic disorders of the two atria, the smaller pair of the heart's four chambers.
"Our findings open a window on cardiac arrhythmogenesis and point the way towards developing a new class of drugs," the scientists say in a study published in the journal Nature.
The tarantula peptide works by blocking the microscopic channels in the muscle cells of the atria. When stretched, these channels trigger a muscle contraction. Atrial fibrillation occurs more often as people age. It is considered a risk because the fluttering can generate blood clots which can move to the brain and cause a stroke, said Denis Noble, professor of cardiovascular physiology at Oxford University.
"This research by the Sachs group is important. I don't think there is any doubt about that." He said few treatments existed for the condition so the findings could prove invaluable to an ageing population.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments